In this review, we summarize the evidences for association of genetic variants with therapeutic response in T2D patients to the common drugs including metformin, DPP-4 inhibitors/GLP1R agonists, sulfonylureas/meglitinides and SGLT-2 inhibitors, as well as we discuss limitations and future directions of pharmacogenetics in the field of T2D. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.